These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 9920511)
21. Are patients with familial hypercholesterolaemia well managed in lipid clinics? An audit of eleven clinics from the Department of Health Familial Hypercholesterolaemia Cascade Testing project. Hadfield SG; Horara S; Starr BJ; Yazdgerdi S; Bhatnagar D; Cramb R; Egan S; Everdell R; Ferns G; Jones A; Marenah CB; Marples J; Prinsloo P; Sneyd A; Stewart MF; Sandle L; Wang T; Watson MS; Humphries SE Ann Clin Biochem; 2008 Mar; 45(Pt 2):199-205. PubMed ID: 18325186 [TBL] [Abstract][Full Text] [Related]
22. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. Bhatnagar D; Morgan J; Siddiq S; Mackness MI; Miller JP; Durrington PN BMJ; 2000 Dec; 321(7275):1497-500. PubMed ID: 11118175 [TBL] [Abstract][Full Text] [Related]
23. Gender- and age-specific trends in coronary heart disease mortality in France from 2000 to 2007: results from the MONICA registers. Wagner A; Arveiler D; Ruidavets JB; Bingham A; Montaye M; Ferrières J; Dallongeville J; Haas B; Ducimetière P Eur J Prev Cardiol; 2014 Jan; 21(1):117-22. PubMed ID: 22718795 [TBL] [Abstract][Full Text] [Related]
24. Severe familial hypercholesterolaemia: current and future management. Farnier M; Bruckert E Arch Cardiovasc Dis; 2012 Dec; 105(12):656-65. PubMed ID: 23199621 [TBL] [Abstract][Full Text] [Related]
25. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. Hague W; Forder P; Simes J; Hunt D; Tonkin A; Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760 [TBL] [Abstract][Full Text] [Related]
26. Cardiovascular risk in patients with treated familial hypercholesterolaemia and patients with severe hypertriglyceridaemia. Way BP; Ball MJ; Thorogood M; Cobbe SM; Mann JI J R Soc Med; 1986 Jul; 79(7):391-4. PubMed ID: 3746800 [TBL] [Abstract][Full Text] [Related]
29. Evidence that men with familial hypercholesterolemia can avoid early coronary death. An analysis of 77 gene carriers in four Utah pedigrees. Williams RR; Hasstedt SJ; Wilson DE; Ash KO; Yanowitz FF; Reiber GE; Kuida H JAMA; 1986 Jan; 255(2):219-24. PubMed ID: 3941501 [TBL] [Abstract][Full Text] [Related]
30. [Prevention of coronary heart disease in familial hypercholesterolemia]. Miserez AR; Keller U Ther Umsch; 1994 Oct; 51(10):671-6. PubMed ID: 7839323 [TBL] [Abstract][Full Text] [Related]
31. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy. Vishwanath R; Hemphill LC J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684 [TBL] [Abstract][Full Text] [Related]
32. Comparison of prognostic usefulness of coronary artery calcium in men versus women (results from a meta- and pooled analysis estimating all-cause mortality and coronary heart disease death or myocardial infarction). Bellasi A; Lacey C; Taylor AJ; Raggi P; Wilson PW; Budoff MJ; Vaccarino V; Shaw LJ Am J Cardiol; 2007 Aug; 100(3):409-14. PubMed ID: 17659919 [TBL] [Abstract][Full Text] [Related]
33. Importance of early recognition of heterozygous familial hypercholesterolaemia. Ryan A; Byrne CD Curr Opin Lipidol; 2015 Aug; 26(4):298-303. PubMed ID: 26103611 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930 [TBL] [Abstract][Full Text] [Related]
35. [Cardiovascular risk factors and prevention in women: similarities and differences]. Sclavo M Ital Heart J Suppl; 2001 Feb; 2(2):125-41. PubMed ID: 11255880 [TBL] [Abstract][Full Text] [Related]
36. High "population attributable fraction" for coronary heart disease mortality among relatives in monogenic familial hypercholesterolemia. Austin MA; Zimmern RL; Humphries SE Genet Med; 2002; 4(4):275-8. PubMed ID: 12172393 [TBL] [Abstract][Full Text] [Related]
37. Detection of familial hypercholesterolaemia: external validation of the FAMCAT clinical case-finding algorithm to identify patients in primary care. Weng S; Kai J; Akyea R; Qureshi N Lancet Public Health; 2019 May; 4(5):e256-e264. PubMed ID: 31054643 [TBL] [Abstract][Full Text] [Related]
38. Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992-2013. Mundal L; Igland J; Ose L; Holven KB; Veierød MB; Leren TP; Retterstøl K Eur J Prev Cardiol; 2017 Jan; 24(2):137-144. PubMed ID: 27794106 [TBL] [Abstract][Full Text] [Related]
39. Contrasting patterns of coronary atherosclerosis in normocholesterolaemic smokers and patients with familial hypercholesterolaemia. Sugrue DD; Thompson GR; Oakley CM; Trayner IM; Steiner RE Br Med J (Clin Res Ed); 1981 Nov; 283(6303):1358-60. PubMed ID: 6797539 [TBL] [Abstract][Full Text] [Related]
40. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Santos RD; Gidding SS; Hegele RA; Cuchel MA; Barter PJ; Watts GF; Baum SJ; Catapano AL; Chapman MJ; Defesche JC; Folco E; Freiberger T; Genest J; Hovingh GK; Harada-Shiba M; Humphries SE; Jackson AS; Mata P; Moriarty PM; Raal FJ; Al-Rasadi K; Ray KK; Reiner Z; Sijbrands EJ; Yamashita S; Lancet Diabetes Endocrinol; 2016 Oct; 4(10):850-61. PubMed ID: 27246162 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]